Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 4/20 | 0.35 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7185049 | 0.93 | MEN1 (0.35) | KCNA5MEN1KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL7042863 | 0.92 | KCNA5 (0.37) | KCNA5ALDH1A1SMN1; SMN2 | |
| SCHEMBL7045973 | 0.91 | PSMB5 (0.40) | KCNA5L3MBTL1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL7042125 | 0.90 | L3MBTL1 (0.39) | KCNA5KMT2AL3MBTL1ALDH1A1LMNA | |
| SCHEMBL7044814 | 0.89 | SGMS2 (0.37) | KCNA5MEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL7049145 | 0.88 | KCNA5 (0.38) | KCNA5KMT2AL3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL7046404 | 0.86 | MAPT (0.35) | KCNA5L3MBTL1ALDH1A1 | |
| SCHEMBL7045323 | 0.80 | MGLL (0.36) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6465152 | 0.80 | MAPT (0.39) | MEN1KMT2AL3MBTL1ALDH1A1LMNA | |
| SCHEMBL7047980 | 0.80 | TBXA2R (0.37) | TBXA2RKCNA5MEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | US | disclosed |
| US-6576630-B1 | Alkanoyl substituted benzooxazoles or naphthooxazoles | AXYS PHARMACEUTICALS, INC. | 2003-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | SERPINB1, CTRL, CTSZ | TBXA2R 3395/4885KCNA5 4351/4885MEN1 4023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.